Trends in Pharmacological Sciences
ReviewNuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications
Section snippets
Allosteric effects induced by agonists
It is well known that ligand binding induces a conformational change in nuclear receptors, and protease digestion and antibody accessibility studies reveal that agonists and antagonists trigger distinct structural alterations of nuclear receptor LBDs. The resolution of the crystal structures of several ligand-free (apo) and ligand-occupied (holo) nuclear receptor LBDs alone or in a complex with co-activator fragments have provided molecular details of the various ligand-induced changes and,
Structural basis of antagonist action
To date, three crystals of nuclear receptor LBDs bound to pure AF-2 antagonists (Fig. 3) have been reported. The structural determination of the ERα LBD in complexes with the selective anti-oestrogens raloxifen16 and 4-hydroxy-tamoxifen12, provided the first structural evidence for the structural basis of antagonism. This principle was recently extended to another subgroup of the nuclear receptor family with the determination of the structure of the retinoic acid receptor α (RARα) LBD bound to
Structural basis for full and partial AF-2 antagonism
In addition to complete antagonists of AF-2 function (e.g.raloxifen and 4-hydroxytamoxifen), AF-2 partial agonists–antagonists (Fig. 3) have been crystallized with the corresponding receptors. All the structures discussed above show a strict correlation between the orientation of the AF-2 helix and their biological activity. However, the ERβ–genistein19 and RXRα–F318A–oleic acid17 LBD structures show that H12 can adopt the antagonist conformation even though the corresponding ligand elicits a
Orphan receptors as new pharmacological targets
Because of its implication in virtually all fundamental physiological functions, the nuclear receptor superfamily offers an exceptional spectrum of targets for the development of therapeutics. In addition, the rapidly growing number of nuclear receptor superfamily members raises the prospects of new targets and new ligands. Indeed, recently, ligands for several of these new nuclear receptors, the so-called orphan receptors1, 22, have been identified. One example are PPARs whose α isotype was
Acknowledgements
We thank Dino Moras and all colleagues of the structural biology group at the IGBMC for sharing unpublished information and instructive discussions. Studies in our laboratory are supported by funds from the INSERM, CNRS, Hôpital Universitaire de Strasbourg (HUS), the Fondation pour la Recherche Médicale, the Ministère de la Recherche et de la Technologie and Bristol-Myers-Squibb.
Glossary
Chemical names
- BMS394 and BMS395:
- R- and S-3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphthalen-2-yl)-acetylamino]-benzoic acid
- BMS614:
- 4-[(4,4-dimethyl-1,2,3,4-tetrahydro-[1, 2′]binaphthalenyl-7-carbonyl)-amino]-benzoic acid
- BMS961:
- racemic mixture of BMS394 and BMS395
- G1262570:
- (2S)-((2-benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl} propionic acid
- GW0072:
- (+/−)-(2S, 5S)-4-(4-(4-carboxyphenyl) butyl)-2-heptyl-4-oxo-5-thiazolidine N,N-dibenzylacetamide
- GW2433:
References (60)
Increasing the complexity of coactivation in nuclear receptor signaling
Cell
(1999)Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
Mol. Cell
(2000)Crystal structure of the ligand-binding domain of the human nuclear receptor PPARγ
J. Biol. Chem.
(1998)Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Mol. Cell
(1999)The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
Cell
(1998)Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains
Mol. Cell
(2000)- et al.
The RXR heterodimers and orphan receptors
Cell
(1995) Terminal differentiation of human breast cancer through PPARγ
Mol. Cell
(1998)- et al.
Nuclear receptor regulation ofcholesterol and bile acid metabolism
Curr. Opin. Biotechnol.
(1999) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway
Cell
(1998)